Evidence map›Paper›PMID 42503515›Full record

ArticleSignal transduction and targeted therapy2026

Bacteria-mimicking cancer cells reprogram macrophages via multiple pattern recognition receptor pathways for cancer immunotherapy.

Seoyoon Song, Dongjun Yu, Haneul Kang, Deborah Lee, Jiye Lee, Sungjun Kwak, Jinhee Park, Lifeng Kang, Stanislav Y Emelianov, Jong-Ho Cha and 3 more

Abstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Seoyoon Song *Department of Biological Sciences and Bioengineering, Inha University, Incheon, 22212, Republic of Korea.ORCID http://orcid.org/0000-0001-6255-3258
Dongjun Yu *Department of Biological Sciences and Bioengineering, Inha University, Incheon, 22212, Republic of Korea.ORCID http://orcid.org/0009-0009-8922-8645
Haneul Kang *Department of Biological Sciences and Bioengineering, Inha University, Incheon, 22212, Republic of Korea.ORCID http://orcid.org/0009-0007-1989-5886
Deborah LeeDepartment of Biological Sciences and Bioengineering, Inha University, Incheon, 22212, Republic of Korea.ORCID http://orcid.org/0000-0002-0503-9014
Jiye LeeDepartment of Biological Sciences and Bioengineering, Inha University, Incheon, 22212, Republic of Korea.
Sungjun KwakDepartment of Biological Sciences and Bioengineering, Inha University, Incheon, 22212, Republic of Korea.
Jinhee ParkDepartment of Biological Sciences and Bioengineering, Inha University, Incheon, 22212, Republic of Korea.
Lifeng KangSchool of Pharmacy, Faculty of Medicine and Health, University of Sydney, Pharmacy and Bank Building A15, Sydney, NSW, 2006, Australia.ORCID http://orcid.org/0000-0002-1676-7607
Stanislav Y EmelianovWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, 30332, USA.ORCID http://orcid.org/0000-0002-7098-133X
Jong-Ho ChaDepartment of Biomedical Sciences, College of Medicine, Inha University, Incheon, 22212, Republic of Korea.ORCID http://orcid.org/0000-0003-2181-7768
Yun Suk HuhDepartment of Biological Sciences and Bioengineering, Inha University, Incheon, 22212, Republic of Korea.ORCID http://orcid.org/0000-0003-1612-4473
Sun Min KimDepartment of Biological Sciences and Bioengineering, Inha University, Incheon, 22212, Republic of Korea. sunmk@inha.ac.kr.ORCID http://orcid.org/0000-0001-8420-637X
Tae-Joon JeonDepartment of Biological Sciences and Bioengineering, Inha University, Incheon, 22212, Republic of Korea. tjjeon@inha.ac.kr.ORCID http://orcid.org/0000-0002-4882-9040

Funding

MOE | Korea Environmental Industry and Technology Institute (KEITI) 2022002980004National Research Foundation of Korea (NRF) RS-2024-00353900National Research Foundation of Korea (NRF) RS-2025-24534134
6 · The paper itself

Abstract

Although macrophages are a powerful cell-based platform for cancer immunotherapy, their antitumor functions, such as phagocytosis and inflammatory responses, are limited by the immunosuppressive tumor microenvironment. Here, we show that decorating cancer cell membranes with bacteria-derived pathogen-associated molecular patterns (PAMPs) initiates phagocytosis and inflammatory responses of macrophages toward cancer cells involving various pattern-recognition receptor signaling pathways. Bacteria-derived PAMPs were formulated into membrane-decorating nanoparticles, and these nanoparticles reprogrammed immunosuppressive macrophages into inflammatory phenotypes. Cancer cell membrane-attached PAMP nanoparticles maintained their immunostimulatory responses, stimulating macrophages' antitumor functions. The fraction of phagocytic macrophages significantly increased when coincubated with membrane-decorated cancer cells, along with an increased secretion of inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Transcriptomic gene ontology analysis revealed that the response of macrophages to PAMP-decorated cancer cells resembled their response to bacteria, involving signaling pathways including inflammatory response and innate immune response. In a mouse model, locally injected membrane-decorating PAMP nanoparticles suppressed tumor growth. The therapeutic effect was more pronounced in combination with the chemotherapeutic drug doxorubicin. Median survival days significantly increased in both the PAMP nanoparticle and the PAMP nanoparticle plus doxorubicin combination group with complete remission cases, compared to the doxorubicin group. Our findings provide insights into the use of macrophages as a cancer immunotherapy modality.

Indexed as

BacteriaImmunotherapyMacrophagesNeoplasmsPathogen-Associated Molecular Pattern MoleculesReceptors, Pattern RecognitionAnimalsCell Line, TumorDoxorubicinHumansInnate Immunity RecognitionMiceNanoparticlesPhagocytosisSignal TransductionTumor MicroenvironmentDoxorubicinPathogen-Associated Molecular Pattern MoleculesReceptors, Pattern Recognition

Identifiers

PMID42503515
PMCPMC13402615

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.